People

The People

Governance grade: C+. Lee & Man Chemical is a textbook Hong Kong family chokehold: 75% of the shares sit with the Chairman-mother (Ms. Wai Siu Kee, 10%) and her son the CEO (Mr. Lee Man Yan, 65%), floating only about 206 million shares — roughly 25% of the company. That alignment is a strength when the dividend is paid, but a profound weakness everywhere else: the board has only three genuinely independent directors against three executives and one "non-executive" who is a former executive; every year the Group transacts hundreds of millions of HK$ with Lee & Man Paper (2314.HK), a separately-controlled family company; and the single share-option grant in the company's history went entirely to the CEO, already its 65% owner. Governance disclosures are clean and the auditor (Deloitte) has signed every year without qualification, but economic alignment with minority shareholders is mediated entirely by the family's willingness to keep paying dividends out of a captive, paper-centric customer relationship.

1. The People Running This Company

Lee Family Ownership (%)

Board Members

Independent Directors

Options Outstanding (000s)

82,500

No Results

This is a two-person company in disguise. Ms. Wai built it in 1976; her son Mr. Lee runs it and owns it. The only other executive with a substantive operating role, Mr. Yang, is a 40-year chlor-alkali lifer who runs Jiangxi plant — useful, but signals no independent succession bench beneath the family. Prof. Chan's 2024 move from Executive to Non-Executive Director is a governance dilution, not an upgrade: the Group no longer has an independent senior scientist in an executive capacity, and his HK$5.0M salary continues (he is paid as Non-Exec almost the same as he was as Exec, which is unusual). The CEO's UBC Commerce degree and public-affairs credentials (Jiangxi CPPCC) are consistent with a competent second-generation family operator in mainland Chinese heavy industry, but there is nothing in the disclosures to suggest deep operational chemistry or engineering expertise — that sits with Mr. Yang and Dr. Tse (R&D Executive Dean) below the Board.

**Succession risk.** Chairman Wai is 79. No named successor-in-waiting. If she steps down, power concentrates further on her 46-year-old son, who already owns 65%. There is no independent Chairman pipeline and no Deputy Chairman.

2. What They Get Paid

No Results

Two facts jump out. First, the CEO's one-time share-option grant in FY2018 and FY2019 — HK$32.7M of non-cash share-based incentive each year — is by far the largest number on the pay schedule, and it went to the person who already owns 65% of the company. The option (14 July 2017, 82.5M shares at HK$3.72, 10% of issued capital, vested April 2022, expires March 2027) is currently in-the-money at the HK$4.85 market price, but the delta is thin. Second, 2022 paid the Chairman HK$11.6M discretionary bonus — her biggest ever — in the year revenue peaked at HK$5.9B. In 2023 the bonus pool collapsed to HK$4.0M as profits fell 65%, which does suggest pay-for-performance at the senior-family level. The three Independent Non-Executive Directors share HK$510k a year of fees — less than the Group spends on a single mid-level engineer. That is modest to the point of being cosmetic; it is hard to attract serious board challenge at those rates.

**Non-Exec pay anomaly.** Prof. Chan received HK$5.0M in FY2023 as a Non-Executive Director — essentially the same as when he was an Executive Director (FY2022: HK$5.0M). HK exchange standards typically reserve salary-level compensation for executive roles. The re-designation may have been cosmetic.

3. Are They Aligned?

No Results

No Results

LMP is owned and controlled by the Lee family (Mr. Lee Man Yan's uncles Dr. Lee Wan Keung / Mr. Lee Man Bun / Mr. Lee Man Chun control LMP). It is the single most important counterparty in the Group's ecosystem.

In FY2023 the Group sold HK$176M of chemical products to LMP (4.3% of revenue), paid LMP HK$78M for electricity and steam at Jiangsu, and received HK$69M from LMP for electricity and steam it sold at Jiangxi. The Group also leases office space and dormitories from LMP at both sites. All transactions are independently-director reviewed, auditor-confirmed within annual caps, and disclosed in detail in the Continuing Connected Transactions section and Note 37.

The structural dependency cuts two ways. Positive: it is hard to imagine LMP — a top-three Chinese paper producer and the family's crown jewel — switching its caustic soda and bleach sourcing away. Negative: the same family that controls 2314.HK sits on both sides of the price negotiation, and the chemical supply relationship is the single largest reason minority shareholders of 0746 should care who runs 2314. The chemical sales pricing is confirmed by INEDs annually but not independently benchmarked against arms-length spot prices in disclosure.

Capital allocation and dilution

Capital allocation is unambiguously shareholder-friendly on the dividend front. 825M shares outstanding are unchanged since 2023 (briefly 860.8M in FY2022 when mild buybacks offset option dilution — 22M shares repurchased and cancelled in FY2022 per the financial statements reference, but no buybacks in FY2023/FY2024). Payout ratio held at 39% for five straight years and jumped to ~50% in FY2024 when results improved. No equity raises in the last seven years. Only one option grant ever (the 2017 CEO grant), capped at 10% of issued capital. This is a conservative dilution record.

**Capital allocation positive.** Six-year compound dividend payout stable at 37–39% through cyclical revenue swing of HK$3.1B → HK$5.9B → HK$4.0B. FY2024 payout ratio expanded to ~50%. No dilutive equity raises. Share count basically flat since IPO-era.

Skin-in-the-game score

Skin-in-the-Game Score (out of 10)

Score: 7/10. The CEO's net worth is overwhelmingly tied to 0746 stock (HK$2.6B of equity at HK$4.85). He takes home minor cash compensation (HK$4.2M in FY2023) and does not appear to be diversifying via option sales — the 2017 options have vested but there is no disclosed exercise-and-sell. That said, the family does not "need" this company to do well in isolation: they control LMP too, meaning the household income diversifies across related entities and could be backstopped by LMP performance. One point is deducted because the 65% stake arrived via a private transfer (Mr. Lee was 60% at end-2018 then 65% at end-2023, reflecting an intra-family/block transfer rather than open-market purchases signalling conviction), and another point is deducted because of the structural RPT web with LMP.

4. Board Quality

No Results

**Board independence concern.** Both long-serving INEDs now exceed the HK Corporate Governance Code's nine-year "long-tenure" threshold. The FY2023 Directors' Report explicitly notes that Mr. Heng Victor Ja Wei "has also served as Independent Non-executive Director of the Company for more than nine years" and that his re-election must therefore go as a separate resolution. Mr. Wan Chi Keung's tenure is longer still. That leaves Mr. Wong King Wai Kirk (appointed March 2023) as the only "fresh" independent voice on a seven-person board otherwise dominated by three executives and an ex-executive Non-Exec who is still paid at executive levels.

No Results

The committee structure is formally correct — all three committees are INED-majority (Rem and Audit are fully INED; Nom has INEDs plus Chairman Wai). Attendance was 3/3 for every director in FY2023 across all board and committee meetings. Deloitte is the auditor and has signed every year without qualification. No regulatory actions, no HKEX censures, no Takeovers Panel matters surfaced in the web research. What is missing is the soft tissue: no ESG specialist, no succession pipeline, no long-tenured-INED rotation plan, and no independent chair to pressure-test the connected-party pricing structure.

5. The Verdict

Governance Grade

C+

Grade: C+ (Competent custodial governance, structurally un-challenging board).

Strongest positives. (1) 75% family ownership plus the CEO's HK$2.6B personal stake align incentives at the top; (2) dividend policy has been disciplined and shareholder-friendly across a full business cycle (payout 37–50% every year since FY2019, no equity issuance since 2017); (3) financial controls are clean — Deloitte audited, no qualified opinions, no reported control failures, no regulatory actions in our search; (4) continuing connected transactions with Lee & Man Paper are comprehensively disclosed, capped, and auditor-confirmed inside caps every year.

Real concerns. (1) The board cannot plausibly challenge the family — three executives, one ex-executive, and two long-tenured "independents" (both now past the Code's nine-year threshold, triggering separate AGM resolutions for their re-election) make the INED role a compliance function, not a governance function; (2) the only share-option grant in the company's 18-year listing history went to the person who already owned 60%+ of the stock, which structurally cannot align anyone else; (3) Chairman Wai is 79 with no disclosed successor plan; (4) the Group's entire business model relies on captive utility and chemical transactions with a family-controlled peer (LMP), a relationship that is disclosed correctly but economically unavoidable; (5) INED compensation (HK$150–180k/year) is too modest to attract senior outside directors who would genuinely push back.

What would most likely move the grade. Upgrade to B: appointment of a genuinely independent non-executive Chairman (or Lead Independent Director) with a 3-year rotation requirement for long-tenured INEDs; a public succession plan for Ms. Wai; a broad-based employee option scheme. Downgrade to C-: any material RPT cap breach with LMP, any auditor change without clean handover, any HKEX disciplinary action, or any sign the CEO is monetising his 2017 option grant before 2027 expiry.

**Bottom line.** Trust the family to pay dividends. Don't expect this board to defend minority shareholder interests in a contested situation. The moat is the Lee family's interest in maintaining the stock's dividend yield — currently ~7% — as a cash-return vehicle for themselves.